Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 197

Results For "CRO"

5088 News Found

KIMS partners with UAIMS Hospital
Healthcare | February 19, 2025

KIMS partners with UAIMS Hospital

This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years


Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025
News | February 19, 2025

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability


EyeQ upgrades eye care facility in Surat
Healthcare | February 18, 2025

EyeQ upgrades eye care facility in Surat

Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand


Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
News | February 17, 2025

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY


Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
News | February 17, 2025

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified


Nectar Life Care launches affordable anti-diabetic range of medicines
News | February 17, 2025

Nectar Life Care launches affordable anti-diabetic range of medicines

Offers affordable, high-quality solutions for diabetes care


AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
People | February 15, 2025

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Richard A. Gonzalez to retire from the board of directors effective July 1, 2025


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News | February 15, 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab


Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
News | February 14, 2025

Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore